Microbot Medical to Enhance Focus on its Core Business and Prioritize Preparations for Regulatory and First in Human Clinical Cases

May 18, 2023

https://www.globenewswire.com/news-release/2023/05/18/2671985/0/en/Microbot-Medical-to-Enhance-Focus-on-its-Core-Business-and-Prioritize-Preparations-for-Regulatory-and-First-in-Human-Clinical-Cases.html

HINGHAM, Mass., May 18, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq:MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today announced its Core Business Focus Program and cost restructuring plan to continue enhancing the focus on its core technology while maximizing available resources to support it. This includes the focus on completing the validation and verification process and completing the planned first- in- human (FIH) clinical cases with its LIBERTY Robotic Surgical System, both expected during the second half of 2023.

Read more at globenewswire.com

Related news for (MBOT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.